Mumbai: Cadila Healthcare said on Thursday it has received US FDA approval to conduct trials for its new molecule entity (NME) ZYGK1 to be used for treating diabetes.
Developed by its own research centre, ZYGK1 is an investigational new drug (IND) application that is orally administered and acts as a glucose sensor in pancreas and regulates glucose metabolism in the liver, the drugmaker said in a statement.
“We have been building a promising pipeline of new molecular entities...” Pankaj Patel, chairman and managing director, Zydus Cadila group, said in a statement.
“Our efforts would help us address the unmet healthcare needs in the focus areas of metabolic disorders and cardiovascular diseases.”
Cadila Healthcare has several NMEs in various stages of clinical trial, it said, adding Cadila’s ZYH1 molecule for treating dyslipidemia was undergoing phase-III trials.
At 11:28 am, shares of Cadila Healthcare were trading at Rs821.8, up 2.35% in a weak Mumbai market.